Gene Expression Changes in Hepatitis C Patients Treated with Peg-Interferon and Ribavirin
Author Information
Author(s): Taylor Milton W, Tsukahara Takuma, McClintick Jeanette N, Edenberg Howard J, Kwo Paul
Primary Institution: Indiana University
Hypothesis
This study aims to determine the kinetics of gene expression during the first 10 weeks of therapy with Pegylated-interferon-alfa2b and ribavirin in HCV patients.
Conclusion
The response to PegIntron/ribavirin was similar to that reported for Pegasys/ribavirin, suggesting that more frequent dosing might improve treatment response.
Supporting Evidence
- Gene expression levels were significantly altered at various time points during treatment.
- 11 out of 20 patients showed a positive response to therapy by week 10.
- The sustained viral response rate was 35% at the end of treatment.
Takeaway
This study looked at how certain genes change when patients with hepatitis C are treated with a specific medicine. It found that these changes happen in a pattern and that giving the medicine more often might help patients more.
Methodology
RNA was isolated from PBMC of treatment-naïve patients at multiple time points during treatment, and gene expression was measured using Affymetrix microarrays.
Limitations
The study had limited power to detect differences between responders and non-responders due to the small sample size.
Participant Demographics
16 males and 4 females, all genotype 1 hepatitis C patients.
Statistical Information
P-Value
p ≤ 0.001
Statistical Significance
p ≤ 0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website